Individuals living with multiple sclerosis (MS) often find that heat and humidity aggravate common MS symptoms. In addition to advice such as using air conditioning and sipping cool beverages throughout the day, individuals living with MS may also benefit from the use of special cooling equipment to help maintain an ideal body temperature.

For the more than 400,000 Americans living with multiple sclerosis (MS), the support of loved ones, care partners and organizations such as the Multiple Sclerosis Association of America (MSAA) is crucial to improving quality of life. To help increase awareness of this disease, MSAA is taking part in observing March as MS Awareness Month.

The member organizations of the Multiple Sclerosis Coalition (MSC) unanimously endorsed the American Academy of Neurology’s (AAN) position statement entitled Availability of Disease Modifying Therapies (DMT) for Treatment of Relapsing Forms of Multiple Sclerosis.

Health experts tout swimming as one of the best all-around, total-body workouts. It builds both strength and cardiovascular endurance, and is well-suited for all ages and abilities.

The Multiple Sclerosis Coalition’s (MSC) entire membership is providing support for bipartisan legislation to establish a data system to track the incidence and prevalence of neurological diseases, including multiple sclerosis. The bill, introduced in the U.S. House of Representatives by Congressmen Michael C. Burgess, M.D., (R-TX), and Chris Van Hollen (D-MD), could lead to a better understanding of the disease and provide new disease targets.

Exercising more often is a popular New Year’s resolution, but one that too often proves difficult to keep. But what if thousands of people living with multiple sclerosis (MS) were counting on you to keep that commitment?

The United States Food and Drug Administration (FDA) recently made some changes to the product labeling for Tecfidera® (dimethyl fumarate). These changes instruct physicians on how to best prescribe the drug for their patients to minimize the potential for certain side effects and adverse events. The revisions are described below; please note that several of the definitions given are from MedlinePlus (from the National Institutes of Health).

On December 1, 2014, Novartis announced that their Phase III INFORMS trial with Gilenya® (fingolimod) for individuals with primary-progressive multiple sclerosis (PPMS) did not meet its primary endpoint. Presently, this disease-modifying therapy, taken orally (by mouth), is approved for the long-term treatment of relapsing forms of MS. The hope was that Gilenya would also prove effective in treating PPMS, a less-common form of MS that presently has no approved treatments available to slow disease activity.